Why the study?
What are the pharmacokinetic and pharmacodynamic considerations of calcium-channel blockers in patients with end-stage renal disease?
What are the pharmacokinetic and pharmacodynamic considerations of calcium-channel blockers in patients with end-stage renal disease?
Calcium-channel blockers are effective and safe antihypertensive agents in ESRD patients that do not require dose adjustment and may offer additional survival and access patency benefits.
No takes yet. Share an insight, caveat, or question.
May support CCB consideration in ESRD hypertension; leaves open prospective trials to confirm survival and patency effects.
Sica et al. (2003) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: